🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Excited to have our research funded by Conquer Cancer, the ASCO Foundation and @SAAswim. Looking forward to bringing more answers and a deeper understanding of the effect of clonal hematopoiesis in solid tumor micro-environments. Special thanks to Koichi Takahashi for his steadfast mentorship.

👉Outstanding lecture & visit by our colleague Prof. Fumikho Ishikawa MD PhD from #RIKEN Japan 🇯🇵 on AML #PDX & #MutliOmics | #SmacMimetic #IAPAntagonist #leusm 🙏🏾 To Koichi Takahashi for the kind & introduction !!! RIKEN | #MPNSM #LCL161 #CIAP1 #XIAP #NFkB Sanam Loghavi, MD صنم لغوی 🔬🧬

Starting Now: FLT3 and Menin Inhibitors in AML. Moderated by: Eunice Wang Eunice Wang MD

Shifting gears to AML to discuss FLT3 and Menin inhibitors. Koichi Takahashi kicks off the session with a lecture on intra-tumor heterogeneity and it's impact on clonal evolution, resistance, and prognosis. #DAVABermudaHeme

"Now that we've talked about all the treatments for MM, we get to talk about the consequences" - Koichi Takahashi kicking off our Emerging Therapies in AML session 😅 #DAVABermudaHeme

In vivo hematopoietic stem cell modification by mRNA delivery | Science science.org/doi/10.1126/sc…

I think we need to talk about how devastating this cancer microbiome refutation paper from Steven Salzberg 💙💛 and colleagues is. It really speaks to how devoid of critical thinking and intellectual depth our glam publishing ecosystem has become. 1/n biorxiv.org/content/10.110…

Congratulations!!

Congrats!

cell.com/trends/cancer/… Our review on clonal evolution of myeloid malignancies is out in Trends in Cancer

Our manuscript describing MB-Predict, a platform for calculating myeloid neoplasia risk, has just been published at Nature Genetics. Thank you to Muxin, Pedro and all our team members and collaborators. See here for more: doi.org/10.1038/s41588…

A very high-yield slide from Koichi Takahashi summarizing high-risk mutations in CHIP #iwAL2023

Our first panel discussion of the day with experts Iannis Aifantis, Koichi Takahashi, Ravi Majeti & Uma Borate - an exciting exchange of ideas! #iwAL2023 #Leusm #Leukemia #AMLsm #HemOnc

Engaging roundtable discussion with Ravi Majeti, Courtney DiNardo, Dr. Uma Borate: Associate Professor & Koichi Takahashi on new #AML Research here at #iwAL2023 Register here to watch all the roundtable discussions from the meeting: 👉 ow.ly/7pNc50PuMWV

👉👉👉Clonal evolution of hematopoietic stem cells after cancer chemotherapy| biorxiv | led by ⁦Koichi Takahashi⁩ | ⁦Jyoti Nangalia⁩ ⁦Muzaffar Qazilbash⁩ ⁦Peggy Goodell⁩ ⁦Nitin Jain⁩ ⁦Rashmi Kanagal-Shamanna, MD⁩ ⁦G Garcia-Manero⁩ biorxiv.org/content/10.110…

I really like this schematic from Koichi Takahashi at #iWAL24 on phenotypic shifts in AML after ven-based therapies … don’t underestimate the tiny monocytic & erythroid clones.. they will come back & haunt you!! Food for thought for us #hematopathologist we need to report and track

Cancer therapies impose a selective bottleneck that predisposes patients to developing clonal hematopoiesis. A review by Koichi Takahashi Daisuke Nakada & Peggy Goodell reveals the distinct clinical implications of therapy-related clonal hematopoiesis.

👉👉👉Proud to share our brand new paper 📑 🚨 just out in Blood Journal ➡️ ➡️➡️ collaborative multi-disciplinary #HowITreat #BPDCN with focus on SCT #bmtsm #leusm #RareDisease 👉 .Mohamed Kharfan-Dabaja, MD, MBA .Andy Lane Naveen Pemmaraju, MD | MD Anderson Cancer Center #endcancer 🙌 doi.org/10.1182/blood.…

Another review published in Journal of Clinical Investigation ! This time with dearest friends and collaborators Peggy Goodell and Daisuke Nakada. We reviewed the landscape of therapy-related clonal hematopoiesis. How it develops and differs from de novo CH. jci.org/articles/view/…